(Q28257026)

English

Golimumab

scientific article

In more languages

Statements

scholarly article

0 references

Golimumab (English)

0 references

4

object named as

Uma Yasothan

0 references

Peter Kirkpatrick

5

object named as

Peter Kirkpatrick

0 references

author name string

Dimitrios A Pappas

1

0 references

Joan M Bathon

2

0 references

Delphine Hanicq

3

0 references

language of work or name

0 references

publication date

September 2009

0 references

Nature Reviews Drug Discovery

0 references

8

0 references

9

0 references

695-6

0 references

Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Fully human antibodies from transgenic mouse and phage display platforms

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Infectious complications of tumor necrosis factor blockade

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD2982

31 March 2020

Identifiers

10.1038/NRD2982

0 references

release_2hvkcxc6fvbfznxjlnxbrrw7fe

1 reference

https://api.fatcat.wiki/v0/release/2hvkcxc6fvbfznxjlnxbrrw7fe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28257026&oldid=2175159945"